menu
    • menu
    [{"orgOrder":0,"company":"Angion Biomedica","sponsor":"CSL Vifor","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Terevalefim","moa":"c-Met","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Angion Biomedica","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Angion Biomedica \/ Vifor Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Angion Biomedica \/ Vifor Pharma"},{"orgOrder":0,"company":"Angion Biomedica","sponsor":"CSL Vifor","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Terevalefim","moa":"c-Met","graph1":"Nephrology","graph2":"Phase III","graph3":"Angion Biomedica","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Angion Biomedica \/ Vifor Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Angion Biomedica \/ Vifor Pharma"},{"orgOrder":0,"company":"Angion Biomedica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"ANG-3777","moa":"HGF","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Angion Biomedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Angion Biomedica \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Angion Biomedica \/ Not Applicable"},{"orgOrder":0,"company":"Angion Biomedica","sponsor":"CSL Vifor","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"ANG-3777","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Angion Biomedica","amount2":0.34000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0.34000000000000002,"dosageForm":"","sponsorNew":"Angion Biomedica \/ Vifor Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Angion Biomedica \/ Vifor Pharma"},{"orgOrder":0,"company":"Angion Biomedica","sponsor":"CSL Vifor","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Terevalefim","moa":"HGF","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Angion Biomedica","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"","sponsorNew":"Angion Biomedica \/ Vifor Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Angion Biomedica \/ Vifor Pharma"},{"orgOrder":0,"company":"Angion Biomedica","sponsor":"CSL Vifor","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Terevalefim","moa":"c-Met","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Angion Biomedica","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Angion Biomedica \/ Vifor Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Angion Biomedica \/ Vifor Pharma"},{"orgOrder":0,"company":"Angion Biomedica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Terevalefim","moa":"HGF","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Angion Biomedica","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Angion Biomedica \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Angion Biomedica \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Terevalefim

    Menu

    Terevalefim

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Angion Biomedica

                            U.S.A arrow
                            Cosmoprof
                            Not Confirmed

                            Angion Biomedica

                            U.S.A arrow
                            Cosmoprof
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Terevalefim

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Phase II

                            Sponsor : CSL Vifor

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Angion and Vifor Pharma Report Topline Results from Phase 2 GUARD Trial of ANG-3777 in Cardiac Surgery-Associa...

                            Details : The results from the Phase 2 GUARD trial of Angion’s ANG-3777 in patients undergoing cardiac surgery involving cardiopulmonary bypass at risk for developing acute kidney injury.

                            Brand Name : ANG-3777

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 09, 2021

                            Lead Product(s) : Terevalefim

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Phase II

                            Sponsor : CSL Vifor

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Angion Biomedica

                            U.S.A arrow
                            Cosmoprof
                            Not Confirmed

                            Angion Biomedica

                            U.S.A arrow
                            Cosmoprof
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Terevalefim

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Angoin and Vifor Pharma Report Topline Results from Phase 2 Guard Trial of ANG-3777 in Cardiac-Surgery Associa...

                            Details : ANG-3777 is a small molecule designed to mimic the biological activity of hepatocyte growth factor (HGF), trial did not meet its primary endpoint of percentage increase in serum creatinine based upon the area under the curve (AUC).

                            Brand Name : ANG-3777

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 09, 2021

                            Lead Product(s) : Terevalefim

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Angion Biomedica

                            U.S.A arrow
                            Cosmoprof
                            Not Confirmed

                            Angion Biomedica

                            U.S.A arrow
                            Cosmoprof
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Terevalefim

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Phase III

                            Sponsor : CSL Vifor

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Angion and Vifor Pharma Report Topline Results from Phase 3 Trial of ANG-3777 in Kidney Transplant Patients at...

                            Details : The overall safety profile of ANG-3777 in this trial was consistent with the overall experience in its clinical development program and consistent with the published literature in this patient population.

                            Brand Name : ANG-3777

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 26, 2021

                            Lead Product(s) : Terevalefim

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Phase III

                            Sponsor : CSL Vifor

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Angion Biomedica

                            U.S.A arrow
                            Cosmoprof
                            Not Confirmed

                            Angion Biomedica

                            U.S.A arrow
                            Cosmoprof
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Terevalefim

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Phase III

                            Sponsor : CSL Vifor

                            Deal Size : $30.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Vifor Pharma and Angion Sign License Agreement for ANG-3777 in Nephrology Indications

                            Details : Under the terms of the agreement, Vifor Pharma will receive an exclusive global license, excluding China, Taiwan, Hong Kong and Macau, for all ANG-3777 nephrology indications.

                            Brand Name : ANG-3777

                            Molecule Type : Small molecule

                            Upfront Cash : $30.0 million

                            November 09, 2020

                            Lead Product(s) : Terevalefim

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Phase III

                            Sponsor : CSL Vifor

                            Deal Size : $30.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Angion Biomedica

                            U.S.A arrow
                            Cosmoprof
                            Not Confirmed

                            Angion Biomedica

                            U.S.A arrow
                            Cosmoprof
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Terevalefim

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Angion Initiates Phase 2 Clinical Trial of ANG-3777 in Patients with Acute Lung Injury Associated with COVID-1...

                            Details : The Phase 2 trial is a multicenter, prospective, randomized, double-blind, placebo-controlled trial to assess safety and efficacy of ANG-3777 in patients hospitalized with confirmed COVID-19 pneumonia.

                            Brand Name : ANG-3777

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 08, 2020

                            Lead Product(s) : Terevalefim

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Angion Biomedica

                            U.S.A arrow
                            Cosmoprof
                            Not Confirmed

                            Angion Biomedica

                            U.S.A arrow
                            Cosmoprof
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Terevalefim

                            Therapeutic Area : Nephrology

                            Study Phase : Phase III

                            Sponsor : CSL Vifor

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Angion to Present Results from Multiple Preclinical and Health Economic Studies at the American Transplant Con...

                            Details : The Company is going to discuss the effect of ANG-3777 on Hepatocyte Growth Factor Receptor c-MET Signaling.

                            Brand Name : ANG-3777

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 29, 2020

                            Lead Product(s) : Terevalefim

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase III

                            Sponsor : CSL Vifor

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Angion Biomedica

                            U.S.A arrow
                            Cosmoprof
                            Not Confirmed

                            Angion Biomedica

                            U.S.A arrow
                            Cosmoprof
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Terevalefim

                            Therapeutic Area : Nephrology

                            Study Phase : Phase III

                            Sponsor : CSL Vifor

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Angion Announces Publication of ANG-3777 Phase 2 Results in the Scientific Journal Transplantation

                            Details : The publication details the results of the administration of ANG-3777 in patients who have undergone deceased-donor kidney transplantation and had signs of kidney injury.

                            Brand Name : ANG-3777

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 05, 2020

                            Lead Product(s) : Terevalefim

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase III

                            Sponsor : CSL Vifor

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth